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Abstract
Introduction Breast cancer patients with HER2/neu
overexpression have poor outcomes with a decrease in disease-
free survival (DFS) and overall survival. The biology of HER2/neu
overexpression in breast tumors in African-American and Latina
women is poorly understood. The purpose of this study is to
understand the clinical significance of activated Akt (phospho-
Akt or pAkt) expression in breast tumors from African-American
and Latina patients with corresponding tissue HER2/neu
overexpression. Cellular and molecular studies have shown that
activation of the cell signaling phosphatidylinositol-3-kinase/Akt
cascade via the HER2/neu and other receptor tyrosine kinases
induces cell proliferation.
Methods A total of 234 African-American and Latina patients
were selected retrospectively. From this group, 141 tumor
tissue samples were analyzed for tissue pAkt by
immunohistochemistry (IHC). This cohort consisted of 46
HER2/neu-positive (3+ by IHC) and 95 HER2/neu-negative
tumors. The prognostic value of activated tissue Akt in relation
to HER2/neu overexpression for DFS was determined.
Results Patients with low pAkt and HER2-negative tumors had
the best DFS. As expected, HER2/neu-overexpressing tumors
with low pAkt had a decrease in DFS. Similarly, those with high
pAkt and HER2-negative tumors also had poor DFS. However,
those with an increase in both HER2 and pAkt had the worst
DFS. An increase in pAkt was significantly associated with
HER2/neu-positive and lymph node-positive breast tumors.
Tumors with high HER2 and high pAkt were metastatic.
Multivariate analysis demonstrated that, in addition to the
common risk factors such as larger tumor size, lymph node
involvement, estrogen receptor/progesterone receptor-negative
tumors, and HER2/neu-positive tumors, overexpression of pAkt
significantly was associated with a decrease in 5-year DFS. A
decrease in DFS with an increase in pAkt was observed in both
HER2/neu-positive and -negative groups. However, the DFS
was similar between HER2/neu-positive/pAkt-negative and
HER2/neu-negative/pAkt-positive groups.
Conclusion Our data suggest that there may be differences in
tumor phenotypes within the HER2/neu-overexpressing breast
cancer patients. The overexpression of pAkt may be a powerful
prognostic marker for predicting DFS and overall survival of
breast cancer patients.
Introduction
Breast cancer is the most common non-dermatologic cancer
among American women and ranks second among cancer
deaths in women. Although breast cancer survival has
improved over the last 30 years, unexplained cancer-related
health disparities still remain between African-Americans and
Caucasians. People with low socioeconomic status still have
the highest rates of both new tumors and cancer deaths. Afri-
can-Americans are at a higher risk to die from cancer than are
other ethnic groups [1]. Several factors have been
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ican women. Most often, late stage at diagnosis has been a
significant contributor. Breast cancer also is the most com-
monly diagnosed cancer and the leading cause of cancer
death among Hispanic/Latina (Latina) women, even though
breast cancer incidence and mortality in Latina women were
not as high as those of African-American and Caucasian
women. Despite recent increases in screening rates, breast
cancer still tends to be diagnosed at a later stage in many
Latina women, when treatment options are more limited. Unin-
sured Latina women are two to three times more likely to be
diagnosed at a later stage [2]. Our medical center is located
in South Central Los Angeles and serves primarily unders-
erved populations, mainly African-American and Latina
patients. Eighty percent of these African-American and Latina
women had no health insurance. Earlier studies from our labo-
ratory have shown that the age of onset of breast cancer for
Latina women is younger than for African-Americans (48 ver-
sus 53 years) and that both of them have advanced stage III/
IV disease at the time of diagnosis and had poor disease out-
come [3].
In general, the association between poor survival and differ-
ences with tumor phenotypes is not well understood in minor-
ity women with breast cancer. There is a need to develop novel
or better therapeutic strategies in the management of breast
cancer in African-American and Latina women. Significant
research efforts are ongoing to better understanding the
molecular basis of breast cancer and the discovery of molec-
ular markers that could predict reliable prognostic or treatment
outcome [4-7]. Experimental studies have suggested that
overexpression of different growth factor receptors in breast
cancer mediates different cell signaling pathways and makes
the cancer cells become less responsive to treatment. These
receptors include insulin-like growth factor receptor and mem-
bers of the epidermal growth factor receptor (EGFR) family,
such as HER1 (EGFR) and HER2 [8-11].
HER2/neu (also called c-erbB2), a cell-surface membrane
receptor, has been identified and recognized to be signifi-
cantly associated with breast cancer recurrence and death in
the last two decades. In general, about 20% to 30% of breast
cancer patients are diagnosed with an aggressive form of can-
cer that is associated with overexpression of the HER2/neu
protein and its gene. HER2/neu-overexpressing tumors fre-
quently become resistant to treatment with tamoxifen and/or
chemotherapy [12-15]. Current treatment regimens combin-
ing trastuzumab (Herceptin) with paclitaxel and/or docetaxel
[16,17] have shown increased response rate. However,
greater than 70% of patients with HER2/neu-overexpressing
tumors show poor response to treatment [18,19]; in these
patients, the overall survival (OS) and the time to relapse are
significantly shorter [17].
Several mechanisms that explain the mode of resistance to
therapy by the chemo agents alone or in combination with tras-
tuzumab have been described [11,20-22]. The phosphatidyli-
nositol-3-kinase (PI3K) and its associated protein kinase B
(Akt) pathways are frequently activated upon stimulation of
various receptor-mediated cellular signals [23-25]. The activa-
tion of this PI3K/Akt signaling in response to growth factor
receptor activation leads to anti-apoptosis and pathogenesis
of cancer [26]. The PI3K/Akt pathway can be activated by sev-
eral growth factors: insulin-like growth factor, epidermal
growth factor, cytokines, and the HER2/neu network. The acti-
vation of Akt results in the downstream regulation of target
molecules: glycogen synthase kinase-3-beta [27], Forkhead
transcription factor [28], caspase-9 [29], and pro-apoptotic
Bcl-2 family member Bad [30]. The final outcome may result in
cellular proliferation or anti-apoptosis [31,32].
Recent studies using clinical specimens have shown that Akt
protein is frequently activated in HER2/neu-overexpressing
breast tumors and is associated with poor prognosis among
tamoxifen-treated patients [33-37]. Studies on Akt status in
relation to prognosis of breast cancer were mostly focused on
patients with estrogen receptor (ER)-positive tumors treated
with hormone therapy [35,36]. There is limited information on
Akt status in patients with ER-negative tumors and the predic-
tive value of Akt on those breast cancer patients. In addition,
most of these studies were done in either Caucasian or Asian
patients [34-36]. In contrast, there is a dearth of studies on
clinical outcome in African-American and Latina patients with
tissue HER2/neu overexpression with a corresponding
increase in activated Akt at the time of initial diagnosis. From
our early studies, we have observed that an increased level of
plasma HER2/neu in both African-American and Latina
women with breast cancer who underwent surgery and com-
pleted chemotherapy was associated with poor outcome and
a reduction in disease-free survival (DFS) [3].
In the present study, we hypothesized that a subgroup of
patients with HER2/neu-overexpressing breast cancer will
also demonstrate an increase in activated Akt in their tumors.
These patients will be resistant to chemotherapy and conse-
quently this group of patients will have a shorter DFS and a
poor OS. The activation of Akt in breast tumors could be a
potential biologic factor that may partially explain the worse
outcome in those minority women with breast cancer. Hence,
our primary goals were (a) to test whether pAkt overexpression
in HER2/neu-overexpressing tumors led to poor outcome
compared with HER2/neu-overexpressing tumors but with
normal or low levels of pAkt, (b) to compare them to levels of
pAkt in HER2/neu-negative tumors, and (c) to focus on Afri-
can-American and Latina patients at our medical center, where
these two populations have similar socioeconomic status and
access to care. We have postulated that the overexpression of
pAkt will lead to poor outcome irrespective of ethnic or racial
differences. We studied a total of 141 patients. The 5-yearPage 2 of 19
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estimated in these minority patients with HER2/neu-positive
and -negative and with or without pAkt in their tumors. Finally,
we have correlated pAkt levels according to the tumor sub-
types and we determined DFS rates.
Materials and methods
Patients
In this study, we were unable to include Caucasians. This is
primarily due the fact that the majority of our patient popula-
tions at our medical center in South Central Los Angeles are
poor and underserved African-American and Latina patients.
The Caucasian population is less than 2.0% and therefore we
are unable to generate a meaningful sample size.
Patients included in this study were self-reported as African-
American and Latina women with breast cancer and had
undergone surgery. They were treated with chemo or adjuvant
chemotherapy at King/Drew Medical Center between 1999
and 2005. Approval from the institution review board was
obtained before initiating the study. Presurgical information,
tumor pathology and histology (that is, TNM [tumor, node,
metastasis] staging, HER2/neu status, and ER or progester-
one receptor [PR] status), and treatment protocol as well as
disease outcome were compiled on patients from our pro-
spective database. The ER/PR status and HER2/neu status
reported in patient pathology reports were determined by
immunohistochemistry (IHC) and provided by Impath, the Can-
cer Information Company (Los Angeles, CA, USA). ER/PR-
positive status was considered as more than 5% staining in
cell nuclei; otherwise, ER and/or PR status was considered as
negative. The expression of HER2/neu protein determined by
IHC was also obtained according to the pathologist's interpre-
tation of the IHC stain. The IHC stain was performed by the
same central laboratory that performed the ER/PR assays. The
IHC was performed with the DAKO HERCEPTest [38] and
scored on a qualitative scale from 0 to 3+. The staining inten-
sities are defined as 3+ positive, which means a strong com-
plete membrane staining in more than 10% of tumor cells; 2+
positive, which is a weak to moderate complete membrane
staining in more than 10% of tumor cells; 1+ positive, which is
faint or barely perceptible partial membrane staining in more
than 10% of tumor cells; and 0 positive, no staining is
observed or membrane staining is observed in less than 10%
of tumor cells. The HER2/neu status was defined as positive
(HER2/neu 3+ determined by IHC) or negative (included
HER2/neu 2+ and 1+/negative determined by IHC) in this
study.
Patients included in this study were also required to have path-
ologically confirmed ductal or lobular breast carcinoma. We
excluded those whose breast cancer was not primary cancer,
had no detailed information on their tumor pathology, and had
not completed treatment protocol for other than clinical rea-
sons. Each patient included in this study had given their
informed consent.
We selected cases (with paraffin blocks) that had known cor-
responding HER2/neu information and whose paraffin slides
for tumor tissue contained more than 10% tumor cells. A total
of 141 patients fulfilled our criteria and were retrospectively
selected. The number of African-American patients was 72
and the number of Latina patients was 69. In this cohort of 141
breast cancer patients, 113 had invasive ductal (106) or lobu-
lar (7) carcinoma and 28 of them had ductal carcinoma in situ
(26) or lobular carcinoma in situ (2). We had follow-up infor-
mation on all 141 patients.
Determination of pAkt expression by 
immunohistochemistry
To perform IHC on human paraffin tissue samples, 4-μ sec-
tions were placed onto poly-prep slides (P0425; Sigma-
Aldrich, St. Louis, MO, USA) and dried at 60°C for 1 hour. The
sections were deparaffinized and hydrated in 100% ethanol
followed by 95% ethanol. For antigen retrieval, paraffin tissue
sections were treated with sodium citrate (10 mM, pH 6.0) for
10 minutes at 95°C and then cooled for 30 minutes at room
temperature. Immunostaining was performed by using a
Vectastain Universal elite ABC kit (PK-6200; Vector Laborato-
ries, Burlingame, CA, USA). Each tissue section was blocked
with 5% normal horse serum for 30 minutes followed by over-
night incubation at 4°C with antibodies specific for phosphor-
Akt (Ser473) (pAkt) (#9271; Cell Signaling Technology, Inc.,
Danvers, MA, USA) and total Akt (#9272; Cell Signaling Tech-
nology, Inc.). Immunostaining was visualized with a streptavi-
din peroxidase reaction using the DAB (3,3'-
diaminobenzidine) kit (SK-4100; Vector Laboratories). The
nuclei were counterstained with hematoxylin before mounting.
Negative-control tests were conducted with samples in the
absence of primary antibody. Similarly, control paraffin slides
with known negative or positive expression of pAkt (IHC con-
firmed and antibody supplied by vendor) were tested along-
side the unknown samples.
Before testing the paraffin tissues for pAkt by IHC, the sensi-
tivity and specificity of pAkt antibody were tested and vali-
dated using human breast cancer cell lines obtained from the
American Type Culture Collection (ATCC) (Manassas, VA,
USA), such as SKBR3 (overexpressing HER2/neu) and MCF7
(expressing moderate levels of HER2/neu). The pAkt levels in
SKBR3 and MCF7 were determined by IHC first and then fur-
ther confirmed by Western blot analysis (Figure 1). A consist-
ent correlation was observed between IHC and Western blot
analysis with respect to the level of pAkt expression in SKBR3
and MCF7 cells. We have also compared the staining level on
tumor and non-tumor sections from the same patient. Figure 2
demonstrates a paired tissue section from a patient with mod-
erately differentiated infiltrating duct carcinoma who under-
went modified radical mastectomy. Figures 2a and 2b are fromPage 3 of 19
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invasive ductal carcinoma and had a clear IHC stain in the
cytoplasm. Figures 2c and 2d are from uninvolved breast
tissues adjacent to the biopsy cavity and had no or very light
stain.
Quantification of immunohistochemistry results
The pAkt expression was detected in the cytoplasm by IHC. A
mixed cytoplasm and nuclear staining was observed in a few
cases. The pAkt protein expression was first evaluated using
microscopy by two investigators independently without any
prior knowledge of clinical information and pathological
parameters. The stain color and intensity ranged from light to
dark brown. We have scored the intensity of staining as 3+
positive (very strong), 2+ positive (clear staining but not as
strong as 3+), 1+ positive (some lighter staining), and nega-
tive (no staining) (Figure 3). Next, the pAkt expression was
quantified using DigiPro software (Labomed, Inc., Culver City,
CA, USA) according to the percentage of tumor area with pos-
itive cytoplasm staining (positive staining tumor area divided
by total tumor area). Each sample was randomized and quan-
tified from five different areas on the tissue slide, and the mean
of five different areas on the slide was calculated. The stand-
ard deviation (SD) was less than 2% for each. The distribution
of mean area of pAkt-positive expression from those tissue
samples was from 0% to 85% (Figure 4a). The quantification
of IHC results of pAkt expression using both microscopy for
intensity level and computer software for areas was confirmed
by the clinical pathologist who was blinded to the origin of the
tissue. There were few cases in which the pathologist disa-
greed with the initial scores. For those cases, we discussed
them with the pathologist and then objectively re-scored them
and re-confirmed them by two pathologists. In final the analy-
sis, we developed the pAkt index by combining stain intensity
in the cytoplasm of tumor cells and percentage of tumor cells
with cytoplasm staining (intensity × positive area). The range
of pAkt index for the majority of cases was from 0 (negative
staining) to 174 (Figure 4b). The median level of the pAkt index
was 36, and the pAkt index was 255 in one case only. In the
following analysis, the level of pAkt expression was evaluated
using the pAkt index either as a continuous variable directly or
categorized as high pAkt (above the median level of the pAkt
index, >36) and low pAkt (less than or equal to the median
level, ≤ 36). The cutoff level was determined after reviewing
different studies (Table 1) [33,36,37,39-43] and further vali-
dated by examining the non-tumor sections from the same
patients in a total of 30 cases. The pAkt levels were either
Figure 1
pAkt expression in human breast cancer cells determined by immuno-histochemi try and Western blo analysis
histochemistry and Western blot analysis. (a) Immunohistochemistry of 
pAkt expression in SKBR3 and MCF7 cells: (i) SKBR3 cells stained 
with pAkt (Ser473) antibody, (ii) SKBR3 cells stained with secondary 
antibody only (negative control), (iii) MCF7 cells stained with pAkt 
(Ser473) antibody, and (iv) MCF7 cells stained with secondary anti-
body only. The arrows indicate very strong pAkt stain in the cytoplasm 
and nuclear areas of SKBR3 cells, whereas light pAkt stain was 
observed in the cytoplasm of MCF7 cells. (b) Western blot analysis on 
total protein from SKBR3 or MCF7 cells using antibodies directed 
against pAkt (Ser473) (top panel) and total Akt (bottom panel).
Figure 2
pAkt expression in tumor and uninvolved tumor tissue from the same atient examined by i munohistochemistry (IHC)
patient examined by immunohistochemistry (IHC). Low-power (a) and 
high-power (b) images from the same tissue section contained in situ 
and invasive ductal carcinoma and had clear IHC stain in the cyto-
plasm. Low-power (c) and high-power (d) images from the same tissue 
section without tumor had no or light staining.Page 4 of 19
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not in tumor tissue sections (Figure 2). Overall, the pAkt index
in those normal sections that had some level of IHC staining
was 10.1 ± 4.7 (mean ± SD), the median level was 11, and
the range was from 4 to 16.
Statistical analysis
All of the analyses were performed with a statistical package,
SPSS (SPSS Inc., Chicago, IL, USA). DFS was defined as the
time from the day of diagnosis by tissue biopsy to the develop-
ment of either local recurrence or distant metastases. Kaplan-
Meier survival curves with log-rank testing were used to
assess the DFS. The RR of reducing DFS was determined by
Cox proportional hazard regression with multivariate analyses.
The personal chi-square test was used to examine the statisti-
cally significant differences between activation of Akt and
other known predictive markers (tumor size, node involvement,
staging, grade, ER/PR status, and HER2/neu status). A p
value of less than 0.05 was considered statistically significant.
Sample size
We have based the information of patients with HER2/neu sta-
tus from our ongoing breast studies. The time of DFS in
patients with HER2/neu-negative tumors was 4.3 years and in
those with HER2/neu 3+ tumors was less than 3 years. To
estimate the study power, we used Epi Infor 2000 (Centers for
Disease Control and Prevention, Atlanta, GA, USA), and PS-
Power and Sample Size Calculation (Department of Biostatis-
tics, Vanderbilt University, Nashville, TN, USA). We expected
that patients with HER2/neu-positive and overexpressing pAkt
would have a shorter DFS than those with HER2/neu-positive
but low pAkt. To have 80% power with 95% confidence, the
sample size should be 149. Therefore, the current sample size
will provide approximately 80% power with 95% confidence.
Results
Evaluation of pAkt expression by immunohistochemistry
The pAkt antibody was tested using human breast cancer cell
lines obtained from the ATCC. These were SKBR3 (overex-
pressing HER2/neu) and MCF7 (expressing low levels of
HER2/neu). The pAkt levels in SKBR3 and MCF7 were deter-
mined by IHC first and then examined by Western blot analysis
(Figure 1). A consistent correlation was observed between
IHC and Western blot analysis with respect to the level of pAkt
expression in SKBR3 and MCF7 cells. We have also com-
pared the staining level in tumor and non-tumor sections from
the same patient. Figure 2 demonstrates paired tissue sec-
tions from a patient with moderately differentiated infiltrating
duct carcinoma who underwent modified radical mastectomy.
Figures 2a and 2b are from a tumor and adjacent biopsy cavity
that contained in situ and invasive ductal carcinoma and
showed clear IHC staining in the cytoplasm. Figures 2c and
2d are from uninvolved breast tissues adjacent to the biopsy
cavity and had no or very light stain.
Figure 3
The intensity of immunohistochemistry staining with pAkt in breast tissue. (a) 3+ positive (intensity was very strong). (b) 2+ positive (clear stain but 
the intensity was not as strong as 3+). (c) 1+ positive (some light stain). (d) Negative (no stain). (a-d) Low-power images. (e-h) High-power images 
corresponding to (a-d), respectively.Page 5 of 19
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scoring method for pAkt. The similarities and differences are
documented in Table 1. From our study, we determined that
both the intensity of the IHC staining of pAkt and the percent-
age of tumor cells stained with pAkt were necessary determi-
nants for the scoring system. Similar methods were used by
other investigators [36,39]. Hence, we developed a pAkt index
by combining both intensity of IHC and percentage of tumor
cells stained as stated in Materials and methods. To validate
our scoring system, we examined non-tumor sections from the
same patients in a total of 30 cases. The pAkt levels were
either lower or undetectable in those non-tumor tissue sec-
tions, but not in tumor tissue sections. Figure 2 demonstrates
one example. Overall, the pAkt index in those normal sections
that had some level of IHC staining was 10.1 ± 4.7 (mean ±
SD), the median level was 11, and the range was from 4 to 16.
Characteristics of patients and their tumor 
clinicopathology
Table 2 provides a description of our patients and their tumor
characteristics. Overall, from a cohort of 141 patients, 51.1%
were African-American and 48.9% were Latina. The difference
in the number of subjects in the study was not statistically
significant.
Age
Fifty-one point eight percent of our subjects were under 50
years of age, whereas 48.2% were above 50 years of age.
There was significant (p = 0.001 to 0.004) difference with the
following parameters: tumor size, lymph node status, American
Joint Committee on Cancer (AJCC) stage, histological grade,
and HER2/neu status. A larger number of tumors were less
than 5 cm, whereas a greater number had positive lymph node
metastasis (63.1%), AJCC stage between 0 and II (62.4%),
and poorly differentiated tumors (69.5%), and 32.6% had
Figure 4
Distribution of pAkt expression. (a) pAkt level determined by immunohistochemistry (IHC) was quantified using DigiPro software (Labomed, Inc., 
Culver City, CA, USA) according to the percentage of tumor area with positive pAkt stain as mentioned in Materials and methods. The x-axis indi-
cates the percentage of tumor area with positive stain. The range of the percentage of tumor area stained positive for pAkt was from 0% (negative 
stain) to 85% and was plotted at 5% intervals. The y-axis indicates the total number of cases at each of the 5% intervals. Each bar represents the 
total number of cases within the indicated percentage of tumor area which was positively stained by pAkt. (b) The box plot describes the distribution 
of pAkt index in 141 patients. The level of pAkt determined by IHC and quantified with DigiPro software represents pAkt index as stated in Materials 
and methods (pAkt index = intensity × percentage of tumor area with positive stain). The range of pAkt index in the 141 patients is described by the 
box plot. The median level of pAkt index was 36. The value 255 was one outlier.Page 6 of 19
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ER/PR+ status whereas 42.6% had ER/PR- status. This differ-
ence was not significant (p = 0.086). Overall, there was no
significant difference between the numbers of patients with
high pAkt (50.4%) compared to those with low pAkt (49.6%).
The pAkt level is measured as pAkt index, and the cutoff value
was 36. Please see Materials and methods for details on the
estimation method for the pAkt index.
pAkt expression in relation to patient characteristics and 
tumor pathology
Next, we examined whether the pAkt levels could be corre-
lated with patient characteristics and tumor pathology (Table
3). Overall, there was no statistical difference in the pAkt levels
in tumor tissues between African-American and Latina
patients. Similarly, there was no statistical difference in the
pAkt levels between patients under or above 50 years of age,
with tumors smaller or larger than 5 cm, between AJCC stage
below or above stage II, and those with ER/PR+ or ER/PR-
tumors. In contrast, pAkt levels were significantly different in
tumor tissues obtained from patients with lymph node metas-
tasis and those with HER2/neu-positive tumors. Patients with
poorly differentiated tumors also had higher pAkt levels,
although the difference was not highly significant (p = 0.094).
These data suggest that pAkt is elevated significantly only in
tumor tissues from patients with lymph node metastasis and
HER2/neu overexpression. We next examined the relationship
between HER2/neu overexpression, pAkt overexpression, and
5-year DFS.
Five-year disease-free survival in relation to HER2/neu 
and pAkt status
The patients in this study were followed up for a mean of 4
years, and the time range of follow-up was 1 to 8 years. How-
ever, when the follow-up period exceeded 5 years, we counted
and reported data only for the first 5 years. A recent review of
cancer statistics confirms that African-American women with
breast cancer have a shorter 5-year OS period [1] and pre-
menopausal African-American women with breast cancer had
a poorer prognosis than postmenopausal African-Americans
[44]. However, the data on breast cancer prognosis in Latina
women are limited. In our study, we had the distinct advantage
of comparing the two ethnic groups who had similar socioeco-
nomic status and access to care. In addition, there was no sig-
nificant difference between our African-American and Latina
patients with respect to their tumor pathology and stage of dis-
ease at the time of diagnosis. Results from Kaplan-Meier sur-
vival analysis from Figure 5a confirm that there is no significant
difference in 5-year DFS between African-American and
Latina women with breast cancer. However, both groups had
a poor 5-year DFS rate. Next, we examined whether the age at
diagnosis had any influence on 5-year DFS. Our data showed
Table 1
Scoring pAkt expression determined by immunohistochemistry
Author/Reference Method and cutoff level Antibody (company) Positive rate, type of cancer, (city)
Stål, et al. [37] >10% strong staining in tumor cells pAkt-Ser473 (Upstate Biotechnology, 
Lake Placid, NY, USA)
27%, breast cancer, (Stockholm, 
Sweden)
Kirkegaard, et al. [36] Above median level of histoscore 
(inter-quartile range)
pAkt-Ser473 (Biosource International, 
Camarillo, CA, USA)
51%, breast cancer, (Glasgow, UK)
Tokunaga, et al. [33] ≥ 10% of cytoplasm staining pAkt-Ser473 (Cell Signaling 
Technology, Inc., Danvers, MA, USA)
34%, breast cancer, (Fukuoka, Japan)
Messersmith, et al. [39] Quantify by Automated Cellular 
Imaging System (ACIS II, 
Chromavision, Inc). (combination of 
staining color, density, and darkness) 
as a continuous variable
pAkt-Ser473 (Cell Signaling 
Technology, Inc.)
High level in tumor, colorectal cancer, 
(Maryland, USA)
Bose, et al. [40] Scoring as 0 to 2 according to 
intensity; 2 (overexpression) means 
staining more than normal cells
pAkt-Ser473 (Cell Signaling 
Technology, Inc.)
36%, breast cancer, (Los Angeles, 
CA, USA)
Massarelli, et al. [41] More than 15% cytoplasm staining pAkt-Ser473 (Cell Signaling 
Technology, Inc.)
46%, tongue cancer, (Houston, TX, 
USA)
Ogino, et al. [42] Tumor cells were scored as negative 
or positive, using normal epithelial 
cells and lymphocytes as reference
pAkt-Ser473 (Cell Signaling 
Technology, Inc.)
14%, colorectal cancer, (Boston, MA, 
USA)
Schmitz, et al. [43] More than 45% tumor cells staining in 
nuclei
pAkt-Ser473 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, 
USA)
88%, breast cancer, (Essen, 
Germany)
Our study Combination of staining intensity and 
percentage of tumor cells as pAkt 
index, according to quartiles of pAkt 
index
pAkt-Ser473 (Cell Signaling 
Technology, Inc.)
50%, breast cancer, (Los Angeles)Page 7 of 19
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study have similar 5-year DFS rates, irrespective of their age at
diagnosis. The overall 5-year DFS rate was about 50%.
Effect of HER2/neu status on 5-year disease-free 
survival
We found that the probability of 5-year DFS was reduced sig-
nificantly in patients with HER2/neu-positive tumors (Figure
6a). The median DFS time was 3.9 years for patients with
HER2/neu-negative tumors but only 2.8 years for those with
HER2/neu-positive tumors. As stated in Materials and meth-
ods, HER2/neu status was measured by IHC methods and
information was obtained from clinical pathology charts.
Effect of pAkt on 5-year disease-free survival
Table 3 had demonstrated that pAkt was significantly associ-
ated with an increase in HER2/neu-overexpressing breast
tumors. We then examined whether the pAkt status had any
influence on 5-year DFS and whether this association was
directly linked to the HER/2neu status. Figure 6b shows that
5-year DFS was significantly reduced in patients with high
pAkt compared with those with low pAkt. In comparison to
Table 2
Patient characteristics




Latina 69 48.9 0.801
Age at diagnosis
<50 years 73 51.8
≥ 50 years 68 48.2 0.674
Tumor size
<5 cm 90 63.8
≥ 5 cm 51 36.2 0.001
Lymph node status
Positive 89 63.1
Negative 52 36.9 0.004
AJCC stage
0–II 88 62.4
III–IV 53 37.6 0.004
Histological grade
Well to moderately differentiated 43 30.5
Poorly differentiated 98 69.5 0.001
ER/PR status
ER/PR+ 81 57.4
ER/PR- 60 42.6 0.086
HER2/neu status
Positive 46 32.6
Negative 95 67.4 0.001
pAkt level
High 71 50.4
Low 70 49.6 0.933
AJCC, American Joint Committee on Cancer; ER/PR, estrogen receptor/progesterone receptor; HER2/neu negative, HER2/neu 2+ and 1+ and 
negative; HER2/neu positive, HER2/neu 3+ determined by immunohistochemistry; pAkt level high, pAkt index of greater than 36 (median level); 
pAkt level low, pAkt index of less than or equal to 36.Page 8 of 19
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levels, we observed the following: (a) HER2/neu
overexpression led to a significant decrease in 5-year DFS,
even in the presence of low pAkt; (b) high pAkt expression in
the presence of HER2/neu-negative tumors led to a poorer 5-
year DFS; and (c) those with both high pAkt and high HER2/
neu tissue expression had the worst outcome, with a 5-year
DFS rate of only 10% to 15% (Figure 7). The differences were
highly significant at a p value of less than 0.0001 and with a
log-rank value of 22.7.
Next, we evaluated the distant metastases and local recur-
rence rates within 5 years in these patients with different
HER2/neu status and pAkt levels. Table 4 shows this evalua-
tion. Overall, patients included in this study had 44% distant
metastases and 7% local recurrence within 5 years. The
frequency of distant metastases was significantly higher in
patients with high pAkt group, regardless of their tumor HER2/
neu status (Table 4). Patients whose breast tumors had both
high HER2/neu and high pAkt1 (61.9%) had the highest asso-
ciation with distant metastases. Local recurrence was highest
in patients with HER2/neu-positive tumors, independent of
pAkt. However, these associations with local recurrence were
not statistically significant, due to a lower number of patients
with recurrence.
Since an increase in pAkt together with high HER2/neu
expression was associated with tumor metastasis, we exam-
Table 3
pAkt expression in relation to patient characteristics and tumor pathology
Number pAkt P value
Median Range
Total 141 36.0 0–255.0
Ethnicity
African-American 72 35.7 0–174.0
Latina 69 36.6 0–255.0 0.992
Age at diagnosis
<50 years 73 31.0 0–255.0
≥ 50 years 68 39.0 0–174.0 0.678
Tumor size
<5 cm 90 32.2 0–174.0
≥ 5 cm 51 36.6 0–255.0 0.117
Lymph node status
Positive 89 45.0 0–255.0
Negative 52 27.5 0–135.0 0.001
AJCC stage
0–II 88 33.3 0–174.0
III–IV 53 42.0 0–255.0 0.160
Histological grade
Well to moderately differentiated 44 30.0 0–174.0
Poorly differentiated 97 40.8 0–255.0 0.094
ER/PR status
ER/PR+ 81 30.0 0–255.0
ER/PR- 60 47.3 0–170.0 0.164
HER2/neu status (IHC)
Positive 46 44.5 0–255.0
Negative 95 30.0 0–168.9 0.009
AJCC, American Joint Committee on Cancer; ER/PR, estrogen receptor/progesterone receptor; HER2/neu negative, HER2/neu 2+ and 1+ and 
negative determined by immunohistochemistry (IHC); HER2/neu positive, HER2/neu 3+ determined by IHC.Page 9 of 19
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reduction in 5-year DFS. We performed Cox regression with
multivariate analysis to identify the RR of reducing 5-year DFS.
Table 5 demonstrates that the following factors contribute sig-
nificantly to a decrease in DFS: larger tumor size, positive
lymph nodes, ER/PR-negative tumors, and HER2/neu-positive
tumors. Most interestingly, in addition to these traditional risk
factors, high pAkt was significantly associated (p < 0.006)
with a decrease in 5-year DFS. Ethnicity (comparing African-
American to Latina patients) and age (under or above 50
years) did not contribute to a decrease in 5-year DFS (Table
5).
pAkt in tumor subtypes and influence on 5-year disease-
free survival
Recent studies have suggested that breast cancer patients
with certain tumor subtypes may be more resistant to therapy
and therefore show a decrease in DFS and OS. Given that
pAkt overexpression is associated with a decrease in DFS, we
then asked whether it is possible that certain tumor subtypes,
classified according to their receptor status, would be more
likely to overexpress pAkt and whether these subtypes may
subsequently have a shorter DFS. Hence, we examined the
effect of high and low pAkt on the following tumor subtypes:
(a) luminal A (ER/PR+ and HER2-), (b) luminal B (ER/PR+ and
HER2+), (c) ER/PR-/HER2+, and (d) basal-like (triple-negative,
ER/PR, and HER2-).
Our data in Table 6 show the levels of pAkt (median pAkt
index) in different tumor subtypes: luminal A (ER/PR and
HER2-), 13.4; luminal B (ER/PR+ and HER2+), 42.3; ER/PR-
and HER2+, 56.3; and basal-like (ER/PR- and HER2-), 35.
These values suggest that pAkt levels are highest in ER/PR-
and HER2+ tumors, followed by luminal B (ER/PR+ and
HER2+), and basal-like (ER/PR- and HER2-) and are least in
luminal A (ER/PR+ and HER2-). In comparison to luminal A
type, the levels of pAkt were higher in luminal B and ER/PR-/
HER2+ with statistical significance at a p value of less than or
equal to 0.005, whereas the basal-like group was significant at
a p value of 0.02.
Next, we examined the relationship between 5-year DFS and
low and high pAkt levels in patients classified under different
tumor subtypes. Figure 8a (luminal A, ER/PR-, and HER2+)
shows a significant difference in DFS between low and high
pAkt (p = 0.0057 and log-rank = 7.64). Tumors with high pAkt
had poor DFS. The luminal B subtype (ER/PR+ and HER2+) in
Figure 8b showed poor DFS with both low and high pAkt lev-
els. Although the difference was not statistically significant
between the low and high pAkt groups, the overall DFS was
Figure 5
Five-year disease-free survival (DFS) in African-American and Latina women with breast cancer. (a) Kaplan-Meier survival curves comparing 5-year 
DFS between African-American (green) and Latina (fuchsia) women. (b) Kaplan-Meier survival curves comparing 5-year DFS in African-American 
and Latina women between less than 50 years of age (green) and above 50 years of age (fuchsia) at the time of diagnosis. The differences between 
the curves were estimated by log-rank test, and a p value of less than 0.05 was considered statistically significant.Page 10 of 19
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Five-year disease-free survival (DFS) in African-American and Latina women with HER2/neu or pAkt status. (a) Kaplan-Meier survival curves were 
used to compare the 5-year DFS between HER2/neu-positive (fuchsia) and HER2/neu-negative (green) tumors. (b) A similar comparison between 
high pAkt (fuchsia) and low pAkt (green) tumors in African-American and Latina women. The differences between the curves were estimated by log-
rank test, and a p value of less than 0.05 was considered statistically significant.
Figure 7
Five-year disease-free survival (DFS) in African-American and Latina patients with either high or low pAkt together with their HER2/neu status. Kap-
lan-Meier survival curves were used to compare the 5-year DFS among patients with low pAkt/HER2- (I, red), low pAkt/HER2+ (II, blue), high pAkt/
HER2- (III, fuchsia), and high pAkt/HER2+ (IV, green). The differences between the curves were estimated by log-rank test, and a p value of less than 
0.05 was considered statistically significant. *p < 0.005, the indicated groups compared to group IV (high pAkt/HER2+). ^p = 0.03, between the 
indicated two groups.Page 11 of 19
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ER/PR- with HER2+ subtype: In this group, patients with high
pAkt had a very poor 5-year DFS (only 20%). In contrast, those
with low pAkt had a DFS of almost 60%. The basal-like tumors
(ER/PR- with HER2-) in Figure 9b showed poor but similar
DFS rates between low and high pAkt levels. Hence, the dif-
ference was not statistically significant.
Next, we compared differences in DFS between the different
tumor subtypes and within the high or low pAkt groups. Figure
10a shows the differences within the low pAkt group. The data
suggest that, in comparison to the luminal A subtype (ER/PR+/
HER2-), the 5-year DFS rate was lower in luminal B (ER/PR+/
HER2+), ER/PR-/HER2+, and basal-like (ER/PR-/HER2-). The
difference was statistically significant (p = 0.05) with the
basal-like group. These observations demonstrate that basal-
like tumors have the worse DFS, despite low levels of tissue
pAkt. Next, when we compared the DFS rates among the
patients with different tumor subtypes with high pAkt, we
observed that all four subtypes had a very poor DFS rate
Table 4
pAkt level in relation to distant metastases and local recurrence
Distant metastases P value Local recurrence P value
Yes (%) No (%) Yes (%) No (%)
HER2+/High pAkt 61.9 38.1 0.007 12.5 87.5 0.259
HER2+/Low pAkt 21.4 78.6 18.2 81.8
HER2-/High pAkt 56.3 43.7 7.1 92.9
HER2-/Low pAkt 31.3 68.7 0 100
HER2+, HER2/neu 3+ determined by immunohistochemistry (IHC); HER2-, HER2/neu 2+ and 1+ and negative determined by IHC; High pAkt, 
pAkt level above median level (>36); Low pAkt, pAkt level of less than or equal to 36.
Table 5
Estimation of relative risk of reduction of disease-free survival in African-American and Latina women with breast cancer using 
multivariate analysis
Relative risk 95% CI P value
Tumor size (≥ 5 cm versus <5 cm) 2.1 1.4–4.0 0.03
Lymph node (positive versus negative) 2.2 1.0–4.8 0.05
ER/PR status (negative versus positive) 1.9 1.0–3.3 0.04
pAkt status (high versus low) 2.5 1.3–4.8 0.006
HER2/neu status (positive versus negative) 1.7 1.0–3.3 0.05
Age (<50 years versus ≥ 50 years) 0.9 0.5–1.7 0.54
Ethnicity (African-American versus Latina) 1.2 0.7–2.2 0.54
CI, confidence interval; ER/PR, estrogen receptor/progesterone receptor; HER2/neu positive, HER2/neu 3+ examined by immunohistochemistry 
(IHC); HER2/neu negative, HER2/neu 2+ and HER2/neu 1+/negative by IHC; pAkt high, the pAkt index level above median level (>36); pAkt low, 
the pAkt index level less than or equal to median level (≤36).
Table 6
pAkt level in different subtypes of breast cancer
Subtype of breast cancer Number pAkt index (median) P value
Luminal A (ER/PR+ and HER2-) 38 13.4
Luminal B (ER/PR+ and HER2+) 44 42.3 0.005
ER/PR- and HER2+ 33 56.0 0.002
Basal-like (ER/PR- and HER2-) 26 35.0 0.02
P values were compared with the luminal A group. ER/PR, estrogen receptor/progesterone receptor.Page 12 of 19
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/10/1/R3(Figure 10b). However, the ER/PR-/HER2+ subtype had the
worse outcome.
Discussion
Among the three human isoforms Akt1, Akt2, and Akt3, it has
been suggested that Akt1 may have an important role in tumor
initiation and tumor growth [45-48]. Breast cancer patients
with high-grade tumors and late stage of diagnosis had
activated Akt1 in their tumor cells and their disease had a poor
outcome [49]. Furthermore, patients who had a poor outcome
to endocrine therapy also had activated Akt1 in their tumor
cells [32]. Akt2 frequently has been found to be upregulated
in HER2/neu-positive breast tumors and may contribute to
tumor aggressiveness and metastases [48,50,51]. Akt3
expression is exclusive to more advance and hormone-inde-
pendent breast cancer cells [52]. In the present study, we
used phosphor-Akt (Ser473) antibody, which detects Akt1
only when phosphorylated at serine 473 and which detects
Akt2 and Akt3 only when phosphorylated at equivalent sites.
Therefore, the activated pAkt in breast tumors in our patient
cohort determined by IHC may not be limited to phosphoryla-
tion of Akt1 or Akt2 only. A study in 280 postmenopausal
Swedish women with breast cancer indicated that expression
of pAkt was significantly associated with both Akt1 and Akt2
staining; however, the correlation was stronger for Akt1 than
for Akt2 [37]. Another study in 402 ERα-positive breast can-
cer patients [36] showed clearly that cytoplasmic Akt1 and
Akt3, but not Akt2, expression was correlated significantly with
pAkt expression. We have also examined the association of
pAkt in relation to Akt1 and Akt2 in our patient cohort. The
mRNA levels of Akt1 and Akt2 were determined by quantita-
tive real-time polymerase chain reaction in 60 samples. The
results indicate that the pAkt protein expression was more
associated with Akt1, and there was a significant correlation
between Akt1 and Akt2 at the mRNA level (data not shown).
Our results with different Akt isoforms are more in agreement
with the Swedish study [37]. Studies with both Japanese and
Swedish women with breast cancer indicated that activation
of pAkt in breast cancer was more likely to be associated with
ER/PR-negative tumors [34,37].
The PI3K/Akt signaling pathway is known to promote growth
factor-mediated cell growth, proliferation, migration, and sur-
vival [53-57]. Activation of the PI3K/Akt signaling pathway by
HER2/neu or other growth factors has been suggested to
contribute to multidrug resistance in breast cancer [10,57]. In
addition, the role of the PI3K/Akt pathway has been investi-
gated in many different types of tumors, including oral, head
and neck, and squamous cell tumors. All of these tumors are
associated with poor prognosis [58-60]. Activation of Akt at
Figure 8
Five-year disease-free survival (DFS) in African-American and Latina women with luminal A and luminal B subtypes of breast cancer versus different le ls of pAkt
levels of pAkt. Kaplan-Meier survival curves were used to compare the 5-year DFS between patients with high pAkt (fuchsia) and low pAkt (green) 
and with luminal A type of tumor (a) and luminal B type of tumor (b). The differences between the curves were estimated by log-rank test, and a p 
value of less than or equal to 0.05 was considered statistically significant. ER, estrogen receptor; PR, progesterone receptor.Page 13 of 19
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therapy and to tamoxifen treatment in Caucasian and Asian
women with breast cancer [34-36]. Recently, the activation of
Akt has been shown in Japanese as well as Caucasian women
with HER2/neu-positive breast cancer [34,37,61]. Conse-
quently, activation of Akt downstream of HER2/neu receptor
may play a key role in the development of resistance to chem-
otherapy and to anti-HER2/neu receptor antibody, trastuzu-
mab, in HER2/neu-overexpressing breast tumors.
Our study was designed to understand the interactions
between activation of tissue Akt with and without correspond-
ing overexpression of HER2/neu for assessment of disease
outcome in African-American and Latina women with breast
cancer. Similar to the data on Caucasian and Japanese
women [34,37,61], the expression of pAkt in breast tumors
from African-American and Latina women in our study was
significantly associated with HER2/neu-positive tumors. As
mentioned in the Introduction and in Materials and methods,
our medical center is located in South Central Los Angeles
and serves primarily underserved populations, mainly African-
American and Latina patients. Since the population of
Caucasians served is less than 2%, we have not included this
group in our study.
The numbers of African-American and Latina patients
recruited in our study were fairly similar, and the two groups
had similar socioeconomic status and access to care. Hence,
we feel confident that our study minimizes possible discrepan-
cies due to non-biological factors. The distribution of patients
below or above 50 years of age was fairly similar in our cohort.
With respect to tumor histopathology, there was a significant
difference (p = 0.001 to 0.004) with the following parameters:
a larger number of tumors were less than 5 cm, whereas a
greater number had positive lymph node metastasis (63.1%),
AJCC stage between 0 and II (62.4%), and poorly differenti-
ated tumors (69.5%), and 32.6% had HER2/neu-positive
tumors. Fifty-seven point four percent had ER/PR+ status
whereas 42.6% had ER/PR- status. This difference was not
significant (p = 0.086).
Overall, there was no statistical difference in the pAkt levels in
tumor tissues between African-American and Latina patients.
Similarly, there was no statistical difference in the pAkt levels
between patients under or above 50 years of age, with tumors
smaller or larger than 5 cm, between AJCC stage below or
above stage II, and those with ER/PR+ or ER/PR- tumors. In
contrast, pAkt levels were significantly different in tumor tis-
sues obtained from patients with lymph node metastasis and
Figure 9
Five-year disease-free survival (DFS) in African-American and Latina women with ER/PR- and HER2+ and basal-like (ER/PR-HER2-) subtypes of breast cancer versus different levels of pAkt
breast cancer versus different levels of pAkt. Kaplan-Meier survival curves were used to compare the 5-year DFS between patients with high pAkt 
(fuchsia) and low pAkt (green) and with ER/PR- and HER2+ tumor (a) and basal-like (ER/PR-/HER2-) tumor (b). The differences between the curves 
were estimated by log-rank test, and a p value of less than or equal to 0.05 was considered statistically significant. ER, estrogen receptor; PR, pro-
gesterone receptor.Page 14 of 19
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ferentiated tumors also had higher pAkt levels, although the
difference was not highly significant (p = 0.094). Similarly, the
level of pAkt in patients with ER/PR-negative tumors was
higher than in patients with ER/PR-positive tumors; however,
this difference was not statistically significant (Table 3).
Hence, our data confirm that pAkt is elevated significantly only
in tumor tissues from patients with lymph node metastasis,
HER2/neu overexpression, and possibly those with ER/PR-
negative tumors.
As we examined the association between HER2/neu overex-
pression and increase in pAkt in our breast cancer patients,
we discovered some unique features. First, more than 70% of
patients with HER2/neu-positive tumors had overexpression
of pAkt, and the high pAkt tumors were associated with posi-
tive lymph nodes. Although a similar study on women in Ger-
many showed that 71% of pAkt-positive tumors were HER2/
neu-positive, they had included both HER2/neu 2+ and 3+
positive patients. In addition, their study was conducted in
patients with node-negative breast cancer [61]. The studies
on Japanese and Swedish women [34,37] showed that 43%
to 44% of HER2/neu-positive tumors had a corresponding
increase in pAkt expression. The HER2/neu-positive tumors in
the Japanese group included HER2/neu 2+ and 3+ as deter-
mined by IHC, and for Swedish group, the positive HER2/neu
was determined using a FACSCalibur Flow Cytometer (BD
Biosciences, San Jose, CA, USA). In comparison, our study
showed that more than 70% of African-American and Latina
women with HER2/neu 3+ positive tumors had overexpres-
sion of pAkt in their tumors at the time of diagnosis. This is the
highest degree of pAkt overexpression reported for any ethnic
group. This observation leads us to speculate that pAkt over-
expression in breast tumors from African-American and Latina
women may be one important factor contributing to their over-
all decrease in DFS. Our data also demonstrate for the first
time that patients with high pAkt but with HER2/neu-negative
tumors also had poor 5-year DFS. Furthermore, multivariate
analysis adjusted for traditional prognostic indicators such as
lymph node involvement, tumor size, HER2/neu status, and
ER/PR status demonstrated that pAkt level alone is a stronger
predictor for a decrease in DFS.
Figure 10
Five-year disease-free survival (DFS) in African-American and Latina women with different levels of pAkt versus different types of breast cancer. 
Patients were grouped as low pAkt (median level of pAkt index of less than or equal to 36) (a) and high pAkt (median level of pAkt index of greater 
than 36) (b). Then Kaplan-Meier survival curves were used to compare the 5-year DFS between patients with different subtypes of tumors: I, luminal 
A type of tumor (green); II, luminal B type of tumor (fuchsia); III, ER/PR- and HER2+ tumor (blue); and IV, basal-like type of tumor (red). The differ-
ences between the curves were estimated by log-rank test, and a p value of less than or equal to 0.05 was considered statistically significant. ER, 
estrogen receptor; N.S., no statistical significance between the curves; PR, progesterone receptor.Page 15 of 19
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(ER/PR-/HER2-) breast cancer may contribute to the poor
prognosis of young African-American women [44]. When we
examined the 5-year DFS pattern with respect to pAkt levels in
connection with HER2/neu status and with tumor subtypes,
we discovered an interesting role for pAkt. In comparison to
patients with HER2/neu-negative tumors and with low pAkt
levels, we observed the following: (a) HER2/neu overexpres-
sion led to a significant decrease in 5-year DFS, even in the
presence of low pAkt; (b) high pAkt expression in the pres-
ence of HER2/neu-negative tumors had poorer 5-year DFS;
and (c) those with both high pAkt and high HER2/neu tissue
expression had the worst outcome, with a 5-year DFS rate of
only 10% to 15%. The differences were highly significant at a
p value of less than 0.0001 and with a log-rank value of 22.7.
When we examined the association of pAkt with distant
metastasis and local recurrence, we observed the following: In
general, patients in our study had 44% distant metastases and
7% local recurrence within 5 years. We were surprised at
such a low local recurrence rate. Interestingly, however, the
frequency of distant metastases was significantly high in
patients with high pAkt regardless of their tumor HER2/neu
status. Patients whose breast tumors had both high HER2/
neu and high pAkt had the highest association with distant
metastases (61.9%). Local recurrence was highest in patients
with HER2/neu-positive tumors, independent of pAkt. We
believe that, in our current study, the association with local
recurrence was not statistically significant, due to a smaller
sample size of patients with local recurrence.
Next, we examined what factors would contribute to a
decrease in 5-year DFS. Using Cox regression with multivari-
ate analysis, we determined that the following contributed sig-
nificantly: larger tumor size, positive lymph nodes, ER/PR-
negative tumors, and HER2/neu-positive tumors. Most inter-
estingly, in addition to these traditional risk factors, high pAkt
was significantly associated (p < 0.006) with a decrease in 5-
year DFS. Ethnicity (comparing African-American to Latina
patients) and age (under or above 50 years) did not contribute
to a decrease in 5-year DFS. Hence, between the African-
American and Latina populations, ethnicity or race is not a sig-
nificant contributor of poor DFS.
Perou and colleagues [62] and Sørlie and colleagues [63] ele-
gantly demonstrated that breast carcinomas can also be sub-
divided based on gene expression analysis. However, it is
unclear whether the DFS and OS rates in these different sub-
types can be influenced by overexpression of pAkt. Given that
pAkt overexpression is associated with a decrease in DFS, we
then asked whether it is possible that certain tumor subtypes,
classified according to their receptor status, would be more
likely to overexpress pAkt and whether these subtypes may
subsequently have a shorter DFS. We examined the effect of
high and low pAkt on the following tumor subtypes: (a) luminal
A (ER/PR+ and HER2-), (b) luminal B (ER/PR+ and HER2+), (c)
ER/PR-/HER2+, and (d) basal-like (triple-negative, ER/PR, and
HER2-). First, our data revealed that pAkt levels were highest
in ER/PR- and HER2+ tumors, followed by luminal B (ER/PR+
and HER2+), and basal-like (ER/PR- and HER2-) and least in
luminal A (ER/PR+ and HER2-). In comparison with luminal A
type, the levels of pAkt were higher in luminal B and ER/PR-/
HER2+ subtypes with statistical significance at a p value of
less than or equal to 0.005. The basal-like group was signifi-
cant at a p value of 0.02. Second, we examined the
relationship between 5-year DFS and low and high pAkt levels
in patients classified under different tumor subtypes. Luminal
A tumors (ER/PR- and HER2+) showed a significant difference
in DFS between low and high pAkt (p = 0.0057 and log-rank
= 7.64). Tumors with high pAkt had poor DFS. Luminal B sub-
type (ER/PR+ and HER2+) also showed poor DFS with both
low and high pAkt levels. Although the difference was not sta-
tistically significant between the low and high pAkt groups, the
overall DFS was considerably lower in tumors with high pAkt.
In the ER/PR-/HER2+ subtype, patients with high pAkt had a
very poor 5-year DFS (only 20%). In contrast, those with low
pAkt had a DFS of almost 60%. The basal-like tumors (ER/PR-
with HER2-) showed poor but similar DFS rates between low
and high pAkt levels. Hence, the difference was not statisti-
cally significant. Finally, we compared differences in DFS
between the different tumor subtypes, but within the high or
low pAkt group. Our data suggest that, in comparison with the
luminal A subtype (ER/PR+/HER2-), the 5-year DFS rate was
significantly lower in luminal B (ER/PR+/HER2+), ER/PR-/
HER2+, and basal-like (ER/PR-/HER2-). However, the differ-
ence was statistically significant (p = 0.05) with the basal-like
group. These observations demonstrate that basal-like tumors
have the worse DFS, despite low levels of tissue pAkt. Next,
when we compared the DFS rates among the patients with dif-
ferent tumor subtypes with high pAkt, we observed that all four
subtypes had a very poor DFS rate. However, the ER/PR-/
HER2+ subtype had the worse outcome.
Conclusion
Our studies confirm that an increase in tissue pAkt expression
in HER2/neu-overexpressing breast cancer patients leads to
poor outcome with a significant decrease in 5-year DFS. We
also show that an increase in pAkt in HER2/neu-negative
patients leads to poor DFS. In addition to established
prognostic markers such as nodal involvement, tumor size, ER/
PR status, and HER2/neu status, pAkt is an independent and
strong predictor for a decrease in DFS. Therefore, pAkt may
prove to be an important therapeutic target. A unique feature
of our study is that more than 70% of African-American and
Latina women with HER2/neu-overexpressing breast tumors
are likely to have an increase in their tissue pAkt levels. This
feature, however, needs to be validated using a larger cohort
of minority patients and be compared to Caucasian patients
with similar socioeconomic status, access to care, and stage
of disease at diagnosis. Several comparative studies betweenPage 16 of 19
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nificant differences in survival rates between the two groups.
African-Americans tend to have poorer outcome [64-66]. It will
be an important opportunity to target pAkt for therapy in these
high-risk populations. Overexpression of pAkt may be a pow-
erful prognostic marker for DFS in breast cancer.
Additional studies are required to understand the role of pAkt
in the development of drug resistance. In this study, we were
not able to ascertain the role of pAkt in HER2/neu-overex-
pressing breast tumors resistant to trastuzumab. This is
because the patients who had received trastuzumab prior to
2004 were very few. Further studies are needed to determine
whether the level of pAkt contributes to resistance to trastuzu-
mab in these minority women with HER2/neu-positive breast
cancer. Biological or genetic differences resulting from muta-
tions in the PI3K pathway could account for the activated Akt
tumors, in addition to mutations or loss of PTEN (phosphatase
and tensin homolog deleted on chromosome 10) in HER2/
neu-overexpressing breast tumors. Any of these factors could
contribute to a poor response to therapy. More studies with a
larger sample size will improve our understanding of the role of
pAkt and poor disease outcome in all patients with breast
cancer.
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